Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALRNNASDAQ:ANEBNASDAQ:EVOKNASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$2.52$1.61▼$5.00$45.72M2.2485,383 shs63,385 shsANEBAnebulo Pharmaceuticals$1.14+5.6%$1.23$0.80▼$3.20$44.37M-1.1318,270 shs8,524 shsEVOKEvoke Pharma$2.58-0.4%$3.17$1.94▼$12.32$3.85M0.3122,659 shs13,903 shsSLGLSol-Gel Technologies$0.78+0.8%$0.55$0.33▼$1.65$21.79M1.24282,679 shs43,744 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics0.00%0.00%0.00%0.00%-57.20%ANEBAnebulo Pharmaceuticals+5.56%+12.87%-26.45%-25.97%-59.14%EVOKEvoke Pharma-0.39%+20.00%-10.42%-41.50%-51.96%SLGLSol-Gel Technologies+0.80%+42.22%+33.03%-11.70%-14.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AANEBAnebulo Pharmaceuticals2.3585 of 5 stars3.53.00.00.03.31.70.0EVOKEvoke Pharma0.7927 of 5 stars0.05.00.00.02.10.80.0SLGLSol-Gel Technologies2.7281 of 5 stars3.53.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics 4.00Strong BuyN/AN/AANEBAnebulo Pharmaceuticals 3.00Buy$8.00601.75% UpsideEVOKEvoke Pharma 0.00N/AN/AN/ASLGLSol-Gel Technologies 3.00Buy$5.00539.22% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AEVOKEvoke Pharma$10.25M0.38N/AN/A($9.26) per share-0.28SLGLSol-Gel Technologies$11.71M1.86N/AN/A$1.67 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.120.00N/AN/AN/A-74.08%-27.93%N/AANEBAnebulo Pharmaceuticals-$8.20M-$0.28N/A∞N/AN/A-119.54%-108.08%5/13/2025 (Estimated)EVOKEvoke Pharma-$7.79M-$4.40N/A∞N/A-71.32%-308.49%-53.66%5/13/2025 (Estimated)SLGLSol-Gel Technologies-$27.24M-$0.34N/AN/AN/A-81.75%-27.17%-22.49%5/19/2025 (Estimated)Latest SLGL, ALRN, ANEB, and EVOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05N/AN/AN/AN/AN/A5/19/2025Q4 2024SLGLSol-Gel Technologies-$0.12N/AN/AN/AN/AN/A5/13/2025Q1 2025EVOKEvoke Pharma-$0.33N/AN/AN/A$3.32 millionN/A3/13/2025Q4 2024EVOKEvoke Pharma-$0.25-$0.49-$0.24-$0.49$3.08 million$3.31 million2/14/2025Q2 2025ANEBAnebulo PharmaceuticalsN/A-$0.09N/A-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/AANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A3.303.30ANEBAnebulo PharmaceuticalsN/A17.5117.51EVOKEvoke PharmaN/A1.441.39SLGLSol-Gel TechnologiesN/A5.815.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%ANEBAnebulo Pharmaceuticals28.40%EVOKEvoke PharmaN/ASLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.10%ANEBAnebulo Pharmaceuticals80.60%EVOKEvoke Pharma6.10%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics921.67 million20.56 millionNot OptionableANEBAnebulo Pharmaceuticals441.09 million5.79 millionNot OptionableEVOKEvoke Pharma41.49 million1.40 millionNot OptionableSLGLSol-Gel Technologies5027.86 million9.33 millionOptionableSLGL, ALRN, ANEB, and EVOK HeadlinesRecent News About These CompaniesSol-Gel, Mayne Pharma enter product purchase agreementApril 17, 2025 | markets.businessinsider.comSol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.April 17, 2025 | finanznachrichten.deSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.April 17, 2025 | globenewswire.comGlobal Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth AnalysisApril 7, 2025 | globenewswire.comSol-Gel Technologies Approves Reverse Share Split and Compensation Policy RenewalApril 1, 2025 | tipranks.comSLGL Gears Up to Report Q4 Earnings: Here's What You Should KnowFebruary 25, 2025 | zacks.comIs Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?February 7, 2025 | finance.yahoo.comSol Gel Technologies Ltd (SLGL) Stock Trading RecapDecember 26, 2024 | bovnews.comIs SolGel Technologies (SLGL) a Great Value Stock Right Now?December 25, 2024 | zacks.comSol-Gel Technologies Reports Strong Q3 2024 ResultsNovember 21, 2024 | markets.businessinsider.comSol-Gel announces 180-day extension to regain compliance with NasdaqNovember 21, 2024 | markets.businessinsider.comSolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should KnowNovember 20, 2024 | zacks.comSol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid RequirementNovember 20, 2024 | markets.businessinsider.comSol-Gel Technologies Third Quarter 2024 Earnings: Beats ExpectationsNovember 18, 2024 | finance.yahoo.comSol-Gel Technologies Ltd.: Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 15, 2024 | finanznachrichten.deSol-Gel Technologies reports Q3 EPS (1c) vs (23c) last yearNovember 15, 2024 | markets.businessinsider.comSol-Gel Technologies Reports Positive Q3 Financials and Strategic MovesNovember 15, 2024 | markets.businessinsider.comSol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue EstimatesNovember 15, 2024 | zacks.comSol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 15, 2024 | globenewswire.comsol gel technologies ltd - SLGLOctober 5, 2024 | foxbusiness.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLGL, ALRN, ANEB, and EVOK Company DescriptionsAileron Therapeutics NASDAQ:ALRNAileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.Anebulo Pharmaceuticals NASDAQ:ANEB$1.14 +0.06 (+5.56%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.15 +0.01 (+0.79%) As of 04/25/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Evoke Pharma NASDAQ:EVOK$2.58 -0.01 (-0.54%) As of 04/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Sol-Gel Technologies NASDAQ:SLGL$0.78 +0.01 (+0.80%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$0.78 +0.00 (+0.23%) As of 04/25/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
